Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu 177 dotatate
- Development stage
- Approved
- Lead developer
- Advanced Accelerator Applications
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog used in peptide receptor radionuclide therapy (PRRT). It consists of the radioactive isotope lutetium-177 chelated to the somatostatin analog peptide DOTATATE. The drug selectively binds to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on many gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Upon binding, it delivers targeted beta radiation directly to tumor cells, causing DNA damage and cell death while sparing most surrounding healthy tissue. Lutetium Lu 177 dotatate is approved for treating adults and children aged 12 years and older with SSTR-positive GEP-NETs, including those originating in the foregut, midgut, or hindgut[1][2][5][9]. It was developed as part of an emerging class of targeted radiopharmaceutical therapies.
- Brand names
- Lutathera
- Other names
- lutetium Lu 177-dotatatelutetium (177Lu) oxodotreotide
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on lutetium Lu 177 dotatate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu 177 dotatate.